Vorapaxar: The missing link in antiplatelet therapy!

Vorapaxar: The missing link in antiplatelet therapy!

Bibliographic Details
Main Author:	Abhijit S Nair
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2017-01-01
Series:	Journal of Anaesthesiology Clinical Pharmacology
Online Access:	http://www.joacp.org/article.asp?issn=0970-9185;year=2017;volume=33;issue=2;spage=269;epage=270;aulast=Nair

Similar Items

Vorapaxar
by: Gianluca Airoldi, et al.
Published: (2013-04-01)

Vorapaxar as an Alternative for Ticagrelor Resistance in Neuroendovascular Intervention
by: James C. Mamaril‐Davis, et al.
Published: (2021-11-01)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus
by: Francesco Franchi, MD, et al.
Published: (2019-11-01)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
by: Farag M, et al.
Published: (2015-07-01)

Abstract 1122‐000043: Vorapaxar as An Alternative for Ticagrelor Resistance in Neuroendovascular Intervention
by: James C Mamaril‐Davis, et al.
Published: (2021-11-01)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
by: Obamiro Kehinde, et al.
Published: (2016-01-01)

Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar
by: Cheng JWM
Published: (2016-06-01)

Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease
by: Justin T. Morrison MD, et al.
Published: (2022-01-01)

Clinical use of vorapaxar as an emerging antithrombin agent: A literature review of current evidence
by: Farjah H Algahtani
Published: (2017-01-01)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
by: Julian Friebel, et al.
Published: (2021-12-01)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
by: Leo Ungar, et al.
Published: (2018-12-01)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
by: Renske H. Olie, et al.
Published: (2019-07-01)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
by: Sean vanDiepen, et al.
Published: (2015-12-01)

Trials of antiplatelet therapy.
by: Bounameaux, H
Published: (1994)

Antiplatelet therapies: An overview
by: Gundu H R Rao
Published: (2016-01-01)

Antiplatelet Therapy Considerations in Women
by: Khadeeja Esmail, et al.
Published: (2019-01-01)

Optimizing antiplatelet / antithrombotic therapy
by: Srijithesh P
Published: (2010-01-01)

TRIALS OF ANTIPLATELET THERAPY - REPLY
by: Baigent, C, et al.
Published: (1994)

DURATION OF DUAL ANTIPLATELET THERAPY
by: O. L. Barbarash
Published: (2016-07-01)

The Missing Link
by: Patrick Jaojoco
Published: (2023-11-01)

The Missing Link
by: Patrick Jaojoco
Published: (2023-11-01)

Missing link
by: Hans Rooseboom
Published: (2023-10-01)

“The Missing Link”
by: Kamesha Spates
Published: (2012-07-01)

Antiplatelet therapy in acute cerebral ischaemia.
by: Sandercock, P, et al.
Published: (1999)

Antiplatelet therapy: aspirin for asymptomatic atherosclerosis?
by: Patrono, C, et al.
Published: (2010)

COVID-19 and the Response to Antiplatelet Therapy
by: Tomáš Bolek, et al.
Published: (2023-03-01)

Prevalence of antiplatelet therapy in patients with diabetes
by: Littenberg Benjamin, et al.
Published: (2005-12-01)

Antiplatelet Therapy in Acute Coronary Syndrome
by: I. M. Kuzmina, et al.
Published: (2022-01-01)

ANTIPLATELET THERAPY IN THE PREVENTION OF CEREBROVASCULAR ACCIDENTS
by: O. V. Rodionova, et al.
Published: (2017-03-01)

Antiplatelet therapy strategies for ischemic stroke
by: M. Yu. Maksimova, et al.
Published: (2017-07-01)

Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients with Peripheral and Chronic Coronary Artery Disease: An Updated Review
by: Giulia Magnani, et al.
Published: (2023-08-01)

Comparison of the Degree of Gastric Mucosal Injury between Patients Who Are Receiving Dual Antiplatelet Therapy or Single Antiplatelet Therapy
by: Yuji Shimada, et al.
Published: (2022-09-01)

Dual Antiplatelet Therapy (DAPT) versus No Antiplatelet Therapy and Incidence of Major Bleeding in Patients on Venoarterial Extracorporeal Membrane Oxygenation.
by: Dawid L Staudacher, et al.
Published: (2016-01-01)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
by: Marie Muthspiel, et al.
Published: (2022-11-01)

ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY
by: E. А. Ushkalova, et al.
Published: (2017-03-01)

MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: N. F. Puchinian, et al.
Published: (2017-03-01)

DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE
by: G. N. Guseva, et al.
Published: (2015-09-01)

Antiplatelet Therapy for Acute Respiratory Distress Syndrome
by: Chuan-Mu Chen, et al.
Published: (2020-07-01)

Sex differences in antiplatelet therapy: state-of-the art
by: Aleksandra Gasecka, et al.
Published: (2023-12-01)

Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy
by: GianMarco Podda, et al.
Published: (2018-10-01)